Company profile
Ticker
SBRA
Exchange
Website
CEO
Mr. Richard K. Matros
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Novus Therapeutics, Inc., Tokai Pharmaceuticals Inc
SEC CIK
Corporate docs
Subsidiaries
1717 Senior Partners, LLC • 2100 Benvoulin Court Holdings, Inc. • 2829-34th Street Holdings, Inc. • 317 Winnipeg St. Holdings Inc. • 3211 Alexis Park Drive Holdings Inc. • 870 Westminster Ave. Holdings, Inc. • Beaumont Senior Partners, LLC • Beavercreek Senior Partners, LLC • Bloomsburg Nominee LLC • Bloomsburg Nominee LP ...
IRS number
272560479
SBRA stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-K
2024 FY
Annual report
19 Feb 25
8-K
Sabra Reports Fourth Quarter 2024 Results; Introduces 2025 Guidance
19 Feb 25
8-K
Departure of Directors or Certain Officers
12 Nov 24
10-Q
2024 Q3
Quarterly report
31 Oct 24
8-K
Sabra Reports Third Quarter 2024 Results; Updates 2024 Guidance
31 Oct 24
424B5
Prospectus supplement for primary offering
7 Aug 24
10-Q
2024 Q2
Quarterly report
7 Aug 24
8-K
Sabra Reports Second Quarter 2024 Results; Increases 2024 Guidance
7 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 24
10-Q
2024 Q1
Quarterly report
8 May 24
Transcripts
SBRA
Earnings call transcript
2024 Q4
20 Feb 25
SBRA
Earnings call transcript
2024 Q3
1 Nov 24
SBRA
Earnings call transcript
2024 Q2
8 Aug 24
SBRA
Earnings call transcript
2024 Q1
9 May 24
SBRA
Earnings call transcript
2023 Q4
28 Feb 24
SBRA
Earnings call transcript
2023 Q3
7 Nov 23
SBRA
Earnings call transcript
2023 Q2
8 Aug 23
SBRA
Earnings call transcript
2023 Q2
8 Aug 23
SBRA
Earnings call transcript
2023 Q1
4 May 23
SBRA
Earnings call transcript
2023 Q1
4 May 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 66.34 mm | 66.34 mm | 66.34 mm | 66.34 mm | 66.34 mm | 66.34 mm |
Cash burn (monthly) | 879.00 k | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 1.97 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 64.36 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 73.2 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2024
96.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 381 |
Opened positions | 54 |
Closed positions | 47 |
Increased positions | 156 |
Reduced positions | 99 |
13F shares | Current |
---|---|
Total value | 3.71 tn |
Total shares | 228.56 mm |
Total puts | 80.70 k |
Total calls | 225.10 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 37.02 mm | $641.19 bn |
Vanguard | 34.99 mm | $606.05 bn |
PFG Principal Financial | 22.11 mm | $382.94 bn |
STT State Street | 12.19 mm | $211.09 bn |
JPM JPMorgan Chase & Co. | 10.31 mm | $178.62 bn |
Geode Capital Management | 6.38 mm | $110.55 bn |
Charles Schwab Investment Management | 4.70 mm | $81.49 bn |
LSV Asset Management | 4.28 mm | $74.16 mm |
NTRS Northern Trust | 4.17 mm | $72.21 bn |
BAC Bank of America | 4.12 mm | $71.40 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Feb 25 | Richard K Matros | Common Stock | Grant | Acquire A | No | No | 0 | 14,676 | 0.00 | 827,240 |
28 Feb 25 | Talya Nevo-Hacohen | Common Stock | Grant | Acquire A | No | No | 0 | 4,874 | 0.00 | 326,881 |
28 Feb 25 | Michael Lourenco Costa | Common Stock | Grant | Acquire A | No | No | 0 | 3,858 | 0.00 | 344,613 |
28 Feb 25 | Jessica Flores | Common Stock | Grant | Acquire A | No | No | 0 | 407 | 0.00 | 72,525 |
28 Feb 25 | Craig A. Barbarosh | Common Stock | Grant | Acquire A | No | No | 0 | 946 | 0.00 | 53,283 |
News
A Glimpse Into The Expert Outlook On Sabra Health Care REIT Through 4 Analysts
2w ago
Citizens Capital Markets Reiterates Market Outperform on Sabra Health Care REIT, Maintains $20 Price Target
2w ago
Sabra Health Care REIT Q4 2024 FFO $0.36 Beats $0.35 Estimate, Sales $182.35M Beat $177.96M Estimate
2w ago
Earnings Scheduled For February 19, 2025
2w ago
Truist Securities Downgrades Sabra Health Care REIT to Hold, Lowers Price Target to $17
1mo ago
Press releases
Sabra Reports Fourth Quarter 2024 Results; Introduces 2025 Guidance
2w ago
Sabra Health Care REIT, Inc. Announces Leadership Promotions
2w ago
Sabra Health Care REIT, Inc. Announces Fourth Quarter 2024 Earnings Release Date and Conference Call; Declares Common Dividend
1mo ago
Sabra Health Care REIT, Inc. Announces Tax Treatment of 2024 Distributions
1mo ago